{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:49:02Z","timestamp":1775209742294,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>IgA nephropathy in children has a potential progression risk over decades of adult life. For this reason, pediatric nephrologists tend to treat the disease from the onset, aiming at halting the pathogenetic processes, based on expert opinion and general confidence with steroids for the lack of large pediatric controlled studies. Glucocorticosteroids are widely used, although without full comprehension of the fine molecular effects on IgAN, mostly based on trials performed in adults. In this review, a critical analysis of adult data is provided for extrapolating information useful for children, with a parallel evaluation of the results of the TESTING Trial, employing oral methylprednisolone, and of the NEFIgArd Trial, using enteric release budesonide. Patients\u2019 characteristics and the scheme of the two studies are surprisingly similar: Nefecon and methylprednisolone showed 40\u201350% proteinuria reduction from baseline, with a fast effect of methylprednisolone (3\u20136\u00a0months) and a similar effect on renal function decline. Large genome-wide studies, above-risk alleles, also discovered risk loci targetable by multiple drugs particularly those involved in the modulation of the mucosal immunity priming of B-cells toward the production of galactose deficient IgA1 (Gd-IgA1). The new KDIGO 2024 guidelines under public review in recent months will lower the proteinuria threshold for treatment to 0.5\u00a0mg\/mg and consider the value of Nefecon in reducing the levels of Gd-IgAI1. The choice between old and new corticosteroids in treating children with IgAN is approaching. In the near future, the genetic data, complemented by blood and urine biomarkers, could be included in tools to guide therapeutic choices and monitoring.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s00467-025-06725-1","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:34:39Z","timestamp":1741185279000},"page":"2121-2131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expected and verified benefits from old and new corticosteroid treatments in IgA nephropathy: from trials in adults to new IPNA-KDIGO guidelines"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5704-3867","authenticated-orcid":false,"given":"Licia","family":"Peruzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-6282","authenticated-orcid":false,"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"6725_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000495751","volume":"5","author":"R Coppo","year":"2019","unstructured":"Coppo R (2019) Pediatric IgA nephropathy in Europe. Kidney Dis (Basel) 5:182\u2013188. https:\/\/doi.org\/10.1159\/000495751","journal-title":"Kidney Dis (Basel)"},{"key":"6725_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/S00467-012-2294-6","volume":"28","author":"Y Shima","year":"2013","unstructured":"Shima Y, Nakanishi K, Hama T et al (2013) Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol 28:71\u201376. https:\/\/doi.org\/10.1007\/S00467-012-2294-6","journal-title":"Pediatr Nephrol"},{"key":"6725_CR3","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/J.KINT.2020.10.033","volume":"99","author":"SJ Barbour","year":"2021","unstructured":"Barbour SJ, Coppo R, Er L et al (2021) Updating the international IgA nephropathy prediction tool for use in children. Kidney Int 99:1439\u20131450. https:\/\/doi.org\/10.1016\/J.KINT.2020.10.033","journal-title":"Kidney Int"},{"key":"6725_CR4","doi-asserted-by":"publisher","unstructured":"2011 kidney disease: improving global outcomes (KDIGO) clinical practice guideline for glomerulonephritis (2012) Chapter 10: immunoglobulin a nephropathy. Kidney Int Suppl (2011) 2:209\u2013217. https:\/\/doi.org\/10.1038\/KISUP.2012.23","DOI":"10.1038\/KISUP.2012.23"},{"key":"6725_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi G et al (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883\u2013887. https:\/\/doi.org\/10.1016\/S0140-6736(98)03563-6","journal-title":"Lancet"},{"key":"6725_CR6","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/NDT\/GFP356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M et al (2009) Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24:3694\u20133701. https:\/\/doi.org\/10.1093\/NDT\/GFP356","journal-title":"Nephrol Dial Transplant"},{"key":"6725_CR7","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMOA1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225\u20132236. https:\/\/doi.org\/10.1056\/NEJMOA1415463","journal-title":"N Engl J Med"},{"key":"6725_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/JAMA.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 318:432\u2013442. https:\/\/doi.org\/10.1001\/JAMA.2017.9362","journal-title":"JAMA"},{"key":"6725_CR9","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/JAMA.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA et al (2022) Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 327:1888\u20131898. https:\/\/doi.org\/10.1001\/JAMA.2022.5368","journal-title":"JAMA"},{"key":"6725_CR10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/J.KINT.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen T, Wied S, Fitzner C et al (2020) After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int 98:1044\u20131052. https:\/\/doi.org\/10.1016\/J.KINT.2020.04.046","journal-title":"Kidney Int"},{"key":"6725_CR11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/J.KINT.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/J.KINT.2021.05.021","journal-title":"Kidney Int"},{"key":"6725_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/S00467-020-04486-7","volume":"36","author":"R Coppo","year":"2021","unstructured":"Coppo R (2021) Treatment of IgA nephropathy in children: a land without KDIGO guidance. Pediatr Nephrol 36:491\u2013496. https:\/\/doi.org\/10.1007\/S00467-020-04486-7","journal-title":"Pediatr Nephrol"},{"key":"6725_CR13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0022-4731(82)90035-8","volume":"16","author":"R Brattsand","year":"1982","unstructured":"Brattsand R, Thal\u00e9n A, Roempke K et al (1982) Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem 16:779\u2013786. https:\/\/doi.org\/10.1016\/0022-4731(82)90035-8","journal-title":"J Steroid Biochem"},{"key":"6725_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2165\/00003495-200060050-00010","volume":"60","author":"KM Hvizdos","year":"2000","unstructured":"Hvizdos KM, Jarvis B (2000) Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 60:1141\u20131178. https:\/\/doi.org\/10.2165\/00003495-200060050-00010","journal-title":"Drugs"},{"key":"6725_CR15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/PPUL.22846","volume":"49","author":"AA Beckhaus","year":"2014","unstructured":"Beckhaus AA, Riutort MC, Castro-Rodriguez JA (2014) Inhaled versus systemic corticosteroids for acute asthma in children. A systematic review. Pediatr Pulmonol 49:326\u2013334. https:\/\/doi.org\/10.1002\/PPUL.22846","journal-title":"Pediatr Pulmonol"},{"key":"6725_CR16","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2165\/00003495-200565140-00005","volume":"65","author":"WE Berger","year":"2005","unstructured":"Berger WE (2005) Budesonide inhalation suspension for the treatment of asthma in infants and children. Drugs 65:1973\u20131989. https:\/\/doi.org\/10.2165\/00003495-200565140-00005","journal-title":"Drugs"},{"key":"6725_CR17","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstr\u00f6m","year":"2017","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117\u20132127. https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0","journal-title":"Lancet"},{"key":"6725_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/J.KINT.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J et al (2023) Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 103:391\u2013402. https:\/\/doi.org\/10.1016\/J.KINT.2022.09.017","journal-title":"Kidney Int"},{"key":"6725_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A et al (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet 402:859\u2013870. https:\/\/doi.org\/10.1016\/S0140-6736(23)01554-4","journal-title":"Lancet"},{"key":"6725_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/NG.787","volume":"43","author":"AG Gharavi","year":"2011","unstructured":"Gharavi AG, Kiryluk K, Choi M et al (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321\u2013329. https:\/\/doi.org\/10.1038\/NG.787","journal-title":"Nat Genet"},{"key":"6725_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/NG.3118","volume":"46","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Li Y, Scolari F et al (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187\u20131196. https:\/\/doi.org\/10.1038\/NG.3118","journal-title":"Nat Genet"},{"key":"6725_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/S41588-023-01422-X","volume":"55","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk K, Sanchez-Rodriguez E, Zhou XJ et al (2023) Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 55:1091\u20131105. https:\/\/doi.org\/10.1038\/S41588-023-01422-X","journal-title":"Nat Genet"},{"key":"6725_CR23","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J et al (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795\u20131803. https:\/\/doi.org\/10.1681\/ASN.2011050464","journal-title":"J Am Soc Nephrol"},{"key":"6725_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2215\/CJN.03270410","volume":"5","author":"MC Hastings","year":"2010","unstructured":"Hastings MC, Moldoveanu Z, Julian BA et al (2010) Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 5:2069\u20132074. https:\/\/doi.org\/10.2215\/CJN.03270410","journal-title":"Clin J Am Soc Nephrol"},{"key":"6725_CR25","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1681\/ASN.2007091052","volume":"19","author":"AG Gharavi","year":"2008","unstructured":"Gharavi AG, Moldoveanu Z, Wyatt RJ et al (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008\u20131014. https:\/\/doi.org\/10.1681\/ASN.2007091052","journal-title":"J Am Soc Nephrol"},{"key":"6725_CR26","doi-asserted-by":"publisher","first-page":"e1006609","DOI":"10.1371\/JOURNAL.PGEN.1006609","volume":"13","author":"K Kiryluk","year":"2017","unstructured":"Kiryluk K, Li Y, Moldoveanu Z et al (2017) GWAS for serum galactose-deficient IgA1 implicates critical genes of the o-glycosylation pathway. PLoS Genet 13:e1006609. https:\/\/doi.org\/10.1371\/JOURNAL.PGEN.1006609","journal-title":"PLoS Genet"},{"key":"6725_CR27","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1681\/ASN.2016091043","volume":"28","author":"DP Gale","year":"2017","unstructured":"Gale DP, Molyneux K, Wimbury D et al (2017) Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol 28:2158\u20132166. https:\/\/doi.org\/10.1681\/ASN.2016091043","journal-title":"J Am Soc Nephrol"},{"key":"6725_CR28","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1002\/1873-3468.14409","volume":"596","author":"BA Strickland","year":"2022","unstructured":"Strickland BA, Ansari SA, Dantoft W, Uhlenhaut NH (2022) How to tame your genes: mechanisms of inflammatory gene repression by glucocorticoids. FEBS Lett 596:2596\u20132616. https:\/\/doi.org\/10.1002\/1873-3468.14409","journal-title":"FEBS Lett"},{"key":"6725_CR29","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2215\/CJN.0000000000000338","volume":"19","author":"CK Cheung","year":"2024","unstructured":"Cheung CK, Barratt J, Carroll K et al (2024) Targeting APRIL in the treatment of IgA nephropathy. Clin J Am Soc Nephrol 19:394\u2013398. https:\/\/doi.org\/10.2215\/CJN.0000000000000338","journal-title":"Clin J Am Soc Nephrol"},{"key":"6725_CR30","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/JCM13040947","volume":"13","author":"RS Lim","year":"2024","unstructured":"Lim RS, Yeo SC, Barratt J, Rizk DV (2024) An update on current therapeutic options in IgA nephropathy. J Clin Med 13:947. https:\/\/doi.org\/10.3390\/JCM13040947","journal-title":"J Clin Med"},{"key":"6725_CR31","doi-asserted-by":"publisher","first-page":"ii28","DOI":"10.1093\/CKJ\/SFAD198","volume":"16","author":"F Caravaca-Font\u00e1n","year":"2023","unstructured":"Caravaca-Font\u00e1n F, Guti\u00e9rrez E, Sevillano \u00c1M, Praga M (2023) Targeting complement in IgA nephropathy. Clin Kidney J 16:ii28\u2013ii39. https:\/\/doi.org\/10.1093\/CKJ\/SFAD198","journal-title":"Clin Kidney J"},{"key":"6725_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMOA2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B et al (2025) Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N Engl J Med 392:531\u2013543. https:\/\/doi.org\/10.1056\/NEJMOA2410316","journal-title":"N Engl J Med"},{"key":"6725_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","volume":"19","author":"J Barratt","year":"2024","unstructured":"Barratt J, Liew A, Yeo SC et al (2024) Phase 2 trial of Cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial. Clin J Am Soc Nephrol 19:452\u2013462. https:\/\/doi.org\/10.2215\/CJN.0000000000000384","journal-title":"Clin J Am Soc Nephrol"},{"key":"6725_CR34","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1038\/SREP04904","volume":"4","author":"XJ Zhou","year":"2014","unstructured":"Zhou XJ, Qi YY, Hou P et al (2014) Cumulative effects of variants identified by genome-wide association studies in IgA nephropathy. Sci Rep 4:4904. https:\/\/doi.org\/10.1038\/SREP04904","journal-title":"Sci Rep"},{"key":"6725_CR35","doi-asserted-by":"publisher","first-page":"572754","DOI":"10.3389\/FIMMU.2020.572754","volume":"11","author":"H Selvaskandan","year":"2020","unstructured":"Selvaskandan H, Shi S, Twaij S et al (2020) Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front Immunol 11:572754. https:\/\/doi.org\/10.3389\/FIMMU.2020.572754","journal-title":"Front Immunol"},{"key":"6725_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/J.KINT.2023.11.003","volume":"105","author":"D Wimbury","year":"2024","unstructured":"Wimbury D, Muto M, Bhachu JS et al (2024) Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial. Kidney Int 105:381\u2013388. https:\/\/doi.org\/10.1016\/J.KINT.2023.11.003","journal-title":"Kidney Int"},{"key":"6725_CR37","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000487903","volume":"43","author":"P Kosztyu","year":"2018","unstructured":"Kosztyu P, Hill M, Jemelkova J et al (2018) Glucocorticoids reduce aberrant o-glycosylation of IgA1 in IgA nephropathy patients. Kidney Blood Press Res 43:350\u2013359. https:\/\/doi.org\/10.1159\/000487903","journal-title":"Kidney Blood Press Res"},{"key":"6725_CR38","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1159\/000494442","volume":"43","author":"J Neuhaus","year":"2018","unstructured":"Neuhaus J, Bauer F, Fitzner C et al (2018) Urinary biomarkers in the prediction of prognosis and treatment response in IgA nephropathy. Kidney Blood Press Res 43:1563\u20131572. https:\/\/doi.org\/10.1159\/000494442","journal-title":"Kidney Blood Press Res"},{"key":"6725_CR39","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/J.EKIR.2024.07.031","volume":"9","author":"J Li","year":"2024","unstructured":"Li J, Lv J, Wong MG et al (2024) Correlation of urinary soluble CD163 levels with disease activity and treatment response in IgA nephropathy. Kidney Int Rep 9:3016\u20133026. https:\/\/doi.org\/10.1016\/J.EKIR.2024.07.031","journal-title":"Kidney Int Rep"},{"key":"6725_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/S00467-024-06502-6","volume":"40","author":"M Vivarelli","year":"2025","unstructured":"Vivarelli M, Samuel S, Coppo R et al (2025) IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol 40:533\u2013569. https:\/\/doi.org\/10.1007\/S00467-024-06502-6","journal-title":"Pediatr Nephrol"},{"key":"6725_CR41","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/IBD\/IZY189","volume":"24","author":"A Hemperly","year":"2018","unstructured":"Hemperly A, Sandborn WJ, Vande CN (2018) Clinical pharmacology in adult and pediatric inflammatory bowel disease. Inflamm Bowel Dis 24:2527\u20132542. https:\/\/doi.org\/10.1093\/IBD\/IZY189","journal-title":"Inflamm Bowel Dis"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06725-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06725-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:18:01Z","timestamp":1748337481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06725-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6725"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06725-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"30 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}